Level Four Advisory Services’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Level Four Advisory Services’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-935	Closed	-$203K	–	876
2023 Q2	$203K	Buy	+935	New	+$200K	0.01%	736

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Level Four Advisory Services's KRTX Position: Q3 2023 in Review

Level Four Advisory Services sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 935 shares — an estimated $203K sold.

Level Four Advisory Services first reported a position in KRTX in Q2 2023 and held it in 1 quarter. The position peaked at $203K in Q2 2023. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

Level Four Advisory Services reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Level Four Advisory Services sold 935 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $203K.
Level Four Advisory Services first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
Level Four Advisory Services's Karuna Therapeutics, Inc. Common Stock position peaked at $203K in Q2 2023.
256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Level Four Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.